Bio-Rad Laboratories BIO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's cash & equivalents?
- Bio-Rad Laboratories (BIO) reported cash & equivalents of $509M in Q1 2026.
- How has Bio-Rad Laboratories's cash & equivalents changed year-over-year?
- Bio-Rad Laboratories's cash & equivalents decreased by 2.7% year-over-year, from $523.1M to $509M.
- What is the long-term trend for Bio-Rad Laboratories's cash & equivalents?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's cash & equivalents has grown at a -4.4% compound annual growth rate (CAGR), from $667.12M to $532.2M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments immediately available to the company.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for future investment, while a decrease may indicate heavy capital expenditure or cash burn.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in life sciences typically maintain high cash balances for M&A flexibility.